Focus Review - The hard technology sector continues to favor embodied intelligence and robotics, with Galaxy General Robotics completing a new round of financing of 2.5 billion yuan, backed by multiple investors including the National Artificial Intelligence Industry Investment Fund and China Petroleum [4][7] - In the health sector, innovative drugs and cell therapies remain significant capital attractors, with Zhitai Bio completing over 500 million yuan in Series C financing led by OrbiMed [4][23] - The internet sector sees major companies increasing investments in AI, with Deep Principle announcing A2 round financing led by Jinma Investment [5][36] Hard Technology - Galaxy General Robotics completed a new round of financing of 2.5 billion yuan, with multiple investors participating [4][7] - Songyan Power announced the completion of B round financing, accumulating nearly 1 billion yuan [4][9] - Yuliqi Robotics completed nearly 300 million yuan in new equity financing, with participation from various investors [4][12] Health Sector - Zhitai Bio completed over 500 million yuan in Series C financing, with continued support from existing shareholders [4][23] - Yimufeng Bio completed nearly 200 million yuan in Pre-IPO financing, led by Gao Rong Venture Capital [4][26] - Huamei Haolian announced the completion of several hundred million yuan in Series D financing [22] Internet Sector - Deep Principle completed A2 round financing, led by Jinma Investment [5][36] - VAST announced the completion of 50 million USD in A round financing, with participation from Alibaba and Hengxu Capital [5][35] - Light Year Touch completed a million-dollar angel round financing [30] Other Notable Financing - Kaal Power completed over 100 million USD in B round financing [8] - Sainade completed over 200 million yuan in strategic financing [13][18] - Proton Automotive completed several hundred million yuan in B round financing [17]

Core Insights - Iovance's Q4 2025 revenue reached $86.77 million, a quarter-over-quarter increase of approximately 30%, with gross margin improving significantly to 50%, marking a shift from "technical validation" to "large-scale commercialization" in the TIL therapy sector [1][2] - Chinese companies, represented by Junshi Biosciences, are innovating to reduce treatment costs and enhance accessibility for TIL therapies, indicating a competitive edge in the market [1][4] Financial Performance - Iovance's stock price surged by 30.8% to $3.78 on the day of the earnings report, marking the largest single-day increase in two years, with after-hours trading pushing it to $3.877 [2] - The revenue of $86.77 million exceeded analyst expectations, and the gross margin increased from 43% in Q3 to 50%, indicating improved production processes and market acceptance [2][3] Clinical Developments - The FDA granted Lifileucel fast track designation for non-small cell lung cancer, with the registration trial expected to complete patient enrollment in the first half of the year [2] - Iovance reported a 50% objective response rate (ORR) in a pilot trial for refractory soft tissue sarcoma, suggesting the TIL technology platform's potential across multiple solid tumor indications [3] Competitive Landscape - Junshi Biosciences is leading a shift in TIL therapy by developing GC101, which does not require high-intensity chemotherapy or IL-2 injections, addressing significant safety and accessibility issues [4][5] - The clinical data for GC101 shows a 41.7% ORR and a 66.7% disease control rate (DCR) in late-stage non-small cell lung cancer, positioning it as a competitive alternative to traditional therapies [6][8] Market Outlook - The period of 2026-2027 is anticipated to be a critical window for TIL therapies, with Iovance's success raising the probability of success for solid tumor cell therapies [9] - Investment strategies are shifting towards assets with confirmed data, differentiated technology, and clear commercialization paths, benefiting companies like Junshi Biosciences [10]

Core Viewpoint - The newly approved olfactory sheath cell therapy technology in China represents a significant advancement in the treatment of stroke sequelae and Parkinson's disease, marking the transition from research to clinical application in the field of neurodegenerative diseases [1][2]. Group 1: Technology Approval and Clinical Application - The olfactory sheath cell therapy has received official approval for clinical application by the National Health Industry Demonstration Zone in Beidaihe, indicating China's leadership in the field of cell therapy for neurological disorders [1]. - This therapy is based on two multi-center, randomized, double-blind, placebo-controlled Phase II clinical trials, demonstrating its safety and efficacy for patients with advanced ischemic stroke and Parkinson's disease [2]. Group 2: Historical Context and Development - The development of this technology can be traced back to 2001 when Professor Huang Hongyun's team first applied olfactory sheath cell technology to treat patients with complete late-stage spinal cord injuries, achieving significant functional recovery [5]. - The successful transition of this technology into clinical practice is attributed to the collaboration between the Beidaihe Rehabilitation Hospital and Professor Huang's team, as well as the supportive policies in the Beidaihe National Life and Health Industry Demonstration Zone [5]. Group 3: Future Implications and Treatment Paradigm Shift - Olfactory sheath cell therapy is considered one of the most effective clinical techniques for repairing central nervous system injuries, and it can be combined with other methods such as neural modulation and neuro-rehabilitation training for comprehensive treatment [5]. - The concept of "comprehensive neural repair treatment" proposed by Professor Huang's team signifies a shift in the treatment paradigm for neurological diseases from traditional symptomatic management to structural and functional repair [5].

Core Viewpoint - The company has signed a strategic cooperation agreement to invest up to RMB 370 million in building an advanced CAR-T cell therapy product commercialization production base in Shanghai, aligning with its commercialization process for multiple CAR-T products [1] Group 1: Investment and Development - The total investment for the new production base is capped at RMB 370 million, which will support the commercialization of existing and upcoming CAR-T cell therapy products [1] - The production base will facilitate the commercialization of the already launched product, Sai Kaize, and the new drug application stage product, Shu Ru Ji Ao Lun Sai injection (tentative name: Kai Li Mei TM) [1] - The investment strategy allows the company to avoid significant capital expenditures early on, preserving cash flow for core R&D and market expansion [1] Group 2: Strategic Importance - The collaboration is seen as a core initiative to enhance CAR-T cell therapy production capacity that meets international standards, crucial for the commercialization of multiple products and strengthening global competitiveness [1] - The agreement reflects the company's robust financial planning and deep engagement in the CAR-T cell therapy industry ecosystem, aligning with national and local biopharmaceutical industry policies [1] - This strategic partnership is expected to solidify the company's leading position in the global CAR-T cell therapy field and create long-term value for shareholders [1]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Shenzhen Immunofoco Biotechnology Co., Ltd. 深圳易慕峰生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向深圳易慕峰生物科技股份有限公司（「本公司」）、本公司的獨家保 薦人、保薦人兼整體協調人、顧問及包銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記 前，本公司不會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀 請，有意投資者務請僅依據於香港公司註冊處處長註冊的本公司招股章程作出投資決定，招股 章程 ...

Core Insights - Yingbairui (Hangzhou) Biopharmaceutical Co., Ltd. successfully completed a nearly 200 million yuan Series B financing, led by Beijing Deep Intelligence Technology Co., Ltd. and supported by notable investors [1][2] - The financing reflects strong market recognition of Yingbairui's core technological capabilities and future development potential, providing robust support for its continued focus on innovative cell therapy [1][2] Financing Details - The Series B financing raised nearly 200 million yuan, which will facilitate Yingbairui's clinical research advancement, large-scale production capacity construction, and commercialization efforts [2] - Deep Intelligence, as the strategic lead investor, aims to leverage its AI-driven drug development advantages to enhance Yingbairui's new drug research decision-making and execution efficiency [2] Company Overview - Yingbairui is a leading company in the global NK cell therapy sector, focusing on cutting-edge tumor immunotherapy and innovative drug development for immune-related diseases, chronic diseases, and CNS diseases [2] - The company has developed a competitive product pipeline based on core technologies such as non-viral vectors and non-gene-modified ACC-NK and tiNK, with several core products already entering clinical stages [2] Future Outlook - The successful financing is expected to accelerate Yingbairui's commercialization process and address unmet clinical treatment needs by providing more safe and effective solutions [2] - With the effective utilization of the newly raised funds, Yingbairui will continue to deepen its focus on innovative cell therapy and core technological breakthroughs [2]

Core Insights - Health Road Co., Ltd. has entered the cell therapy field through a strategic partnership with He Yuan Biotechnology (Shanghai) Co., Ltd., marking a significant step in building a comprehensive health service ecosystem [1] - The collaboration with He Yuan Biotechnology, a company listed on the STAR Market, enhances Health Road's capabilities in the cell and gene therapy sector, leveraging He Yuan's integrated platform for research, production, and application [1] - Health Road's existing digital health service platform, with 211.8 million registered users and 905,000 registered doctors, aligns well with the new focus on cell storage, preparation, and exosome preparation [1] Business Model and Strategy - On the B2B side, Health Road has established a network covering over 11,000 medical institutions, enhancing customer loyalty and service value through cell technology support [2] - For the C2C segment, the company plans to introduce innovative product combinations such as "cell storage + health assessment" and "exosome anti-aging + medical health services" to maximize user lifecycle value [2] - The enterprise service segment aims to design innovative products like "insurance + cell therapy" for partners in insurance and banking, further extending the service chain [2] Competitive Advantage - The synergistic effect of this strategy allows Health Road to leverage existing resources for rapid expansion without the need to build clinical channels and user trust from scratch [2] - The strategic positioning in the cell biotechnology sector is seen as forward-looking, utilizing a light asset and strong synergy model to avoid heavy R&D investment risks while maximizing existing ecosystem advantages [2] - As the business model is validated and implemented, Health Road is expected to carve out a unique path in the cell therapy field, creating sustainable growth value for investors [2]

Core Insights - CAR-T cell therapy offers hope for patients with relapsed refractory hematologic malignancies, but traditional therapies face challenges such as high doses, expensive costs (over 1.2 million yuan per treatment), poor efficacy in solid tumors, and high risk of side effects [1] - Shenzhen Lyman Bio has developed a low-dose metabolically enhanced CAR-T cell therapy based on its innovative immune metabolic reprogramming technology, redefining industry standards in cell therapy [1] Group 1 - The company was co-founded by Professor Tang Li from EPFL and Dr. Guo Yugang, in collaboration with Jingtai Technology, and is currently in the clinical stage of developing innovative immune metabolic drugs [1] - The core technology, Meta10, significantly enhances T cell anti-exhaustion capabilities and the formation of stem-like immune memory cells, addressing T cell exhaustion at its source [1] - The company has received multiple accolades, including the "Disruptive Technology Innovation" key project under the 2025 National Key R&D Program and the "Honor Award" at a major competition, and is recognized as a "potential unicorn enterprise" in Shenzhen for 2025 [1] Group 2 - Based on the Meta10 technology platform, Lyman Bio has developed multiple core research pipelines, including metabolically enhanced CAR-T and TILs, with the CAR-T therapy showing a groundbreaking advantage of a dosage only one-thousandth of conventional commercial CAR-T [2] - As of October 2025, all over 20 patients with relapsed refractory leukemia/lymphoma enrolled in the first batch achieved complete remission (CR) without severe cytokine storm side effects during treatment [2] Group 3 - The company has made significant progress in expanding indications, including the first patient with systemic lupus erythematosus receiving treatment in March 2025, achieving complete remission without medication [4] - In April, the first patient with relapsed refractory chronic lymphocytic leukemia achieved complete remission, and in July, clinical studies for metabolically enhanced BCMA CAR-T for relapsed/refractory plasma cell tumors and IIT studies for advanced solid tumors were initiated [4] - The technology has significantly reduced the cost structure of cell therapy, with future treatment costs expected to drop below 300,000 yuan due to low-dose design and automation processes [4] Group 4 - Lyman Bio has established multiple pipelines, including metabolically enhanced IL-10 CAR-T, TCR-T, TILs, and IL-10-Fc fusion proteins, with the IL-10-Fc fusion protein showing a cure rate increase from 0% to 90% in various solid tumor models during preclinical studies [5] - The company aims to continue advancing clinical research for solid tumors and improve production processes to further reduce the total production cost of CAR-T, benefiting more patients [5]

Core Viewpoint - Health Road (02587.HK) has entered the cell therapy sector through a strategic partnership with He Yuan Bio (688238.SH), marking a significant step in building a comprehensive health service ecosystem and demonstrating its intent to rapidly position itself in the industry using a light-asset model [1][2]. Group 1: Differentiated Strategy - The industry is witnessing significant investments, such as ByteDance's 6 billion yuan commitment to a medical complex, highlighting the value of the cell therapy sector [2]. - Health Road adopts a pragmatic approach by leveraging regional agents and ecosystem collaboration, contrasting with the heavy asset investment strategies of industry giants [2]. - He Yuan Bio, a listed company on the Sci-Tech Innovation Board, has established an integrated platform for research, production, and application in cell and gene therapy, showcasing strong industrial capabilities and technical reserves [2]. Group 2: Business Model and Financial Performance - Health Road's proactive business structure optimization has led to an increase in gross margin to 31.2%, indicating improved profitability [3]. - The cell storage and preparation business typically features high gross margins and prepayment characteristics, which will further enhance the company's revenue structure and provide stable cash flow [3]. - With the cell therapy market growing at an annual rate exceeding 50%, this strategic positioning opens new growth avenues for the company [3]. Group 3: Ecosystem Synergy - The new cell therapy business can quickly integrate with Health Road's existing network of over 11,000 medical institutions, enhancing customer loyalty and service value [4]. - The company can leverage its 211.8 million registered users to introduce innovative product combinations, such as "cell storage + health assessment" and "exosome anti-aging + medical health services," maximizing user lifecycle value [4]. - By designing innovative products like "insurance + cell therapy" for partners in insurance and banking, the company can further extend its service chain [4]. Group 4: Strategic Positioning - Health Road's entry into the cell biotechnology sector represents a forward-looking strategic positioning, utilizing a light-asset and strong synergy model to tap into a high-growth market [4]. - This approach minimizes the risks associated with heavy R&D investments while maximizing the use of existing ecosystem advantages [4]. - As the business gradually takes shape and the model is validated, Health Road is expected to carve out a unique path in the cell therapy field, creating sustainable growth value for investors [4].

Core Insights - The cell therapy market is experiencing rapid growth, with an average annual growth rate exceeding 50%, and is expected to reach a market size of 58.4 billion yuan by 2030 [1] - The implementation of the new regulations for biomedical technology clinical research and application, effective from May 1, 2026, is seen as a foundational law for the industry, promoting a shift towards a comprehensive health management approach [1] Group 1: Company Strategy - Health Road has entered the cell therapy sector through a strategic partnership with He Yuan Bio, indicating its intent to build a comprehensive health service ecosystem [1][2] - The company adopts a light-asset model, focusing on regional agency as a practical approach to accelerate its growth in the cell therapy market [2] - Health Road's collaboration with He Yuan Bio, a company with a robust integrated platform in cell and gene therapy, enhances its industrial capabilities and technological reserves [2] Group 2: Market Positioning - Health Road has established a vast network with 211.8 million registered users and 905,000 registered doctors, allowing it to leverage its existing resources for rapid business expansion [2][4] - The company is focusing on three core areas: cell storage, cell preparation, and exosome preparation, aligning with its comprehensive health service system [2] - The cell storage and preparation business typically has high gross margins and prepayment characteristics, which will further optimize the company's revenue structure and provide stable cash flow [3] Group 3: Competitive Advantage - Health Road's ecosystem enables it to quickly form multi-dimensional synergies, enhancing customer loyalty and service value through its network of over 11,000 medical institutions [4] - The company can introduce innovative product combinations to its vast user base, maximizing user lifecycle value [4] - By leveraging existing resources, Health Road can achieve rapid expansion without the need to build clinical channels and user trust from scratch [4]